|Bid||53.01 x 800|
|Ask||62.80 x 1200|
|Day's Range||62.39 - 63.86|
|52 Week Range||34.94 - 66.01|
|Beta (5Y Monthly)||1.22|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Here's the 2020 economic forecast from a Boston CEO, a leader in commercial real estate, and two top professors.
Less than a year after moving into its new home at Boston’s North Station, cybersecurity company Rapid7 Inc. plans to expand its headquarters by 67,000 square feet at The Hub on Causeway by late 2021, CEO Corey Thomas confirmed to the Business Journal Thursday. The expansion will allow Rapid7 (Nasdaq: RPD) to bring on an additional 400 employees. The company opened its 147,000-square-foot headquarters at 120 Causeway St. — the low-rise loft office space at The Hub on Causeway, a $1.2 billion mixed-use project at North Station and TD Garden — last August.
Intensified U.S.-Iran tensions have raised cybersecurity concerns given the previous cyber-attacks launched by the latter. This should give a boost to cybersecurity stocks.
Futures: Software has rejoined stock market rally, as Salesforce, Dynatrace and Rapid7 broke out. Vertex, Dexcom, Insulet staged bullish rebounds.
With EPS growth rebounding to 111%-125% over the last three quarters, Rapid7 has become one of the top cybersecurity stocks to watch as it nears a new buy point.
There are over 2,800 stocks traded on the NYSE, and thousands more on the world’s other stock exchanges. But with so many stocks out there, and so much information coming in, how do you make sense of it? TipRanks has an answer for that.The Smart Score brings together the disparate data streams in the TipRanks database and distills them down to a single number – a score that you can use to get a sense of what the data means. The analyst consensus, TipRanks’ original rating derived from the published notes of Wall Street’s financial analyst corps, is of course included, but it’s combined with 7 additional factors. The opinions of financial bloggers – another 7,000 experts who follow the markets closely – are considered, as are the sentiment of news articles, the trading moves of corporate insiders, and the activity of individual investors. Movements in traditional technical and fundamental factors are also added in.The resulting score gives a macro view of the stock, based on the most current data available. The Smart Score isn’t a perfect predictor, but it can indicate a direction – will your favorite stock outperform the market, stay neutral, or underperform? It’s the question you need to answer before you put your money down.Today, we’ll look at three tech stocks, each with a “Perfect 10” according to the Smart Score. We’ll see why these companies scored so highly, and what Wall Street’s analysts have to say about it.SS&C Technologies Holdings, Inc. (SSNC)Connecticut-based SS&C is a software and SaaS company with global reach and offices across the Americas, and in Europe, Asia, Australia, and Africa. The company offers products for the financial industry, in fund administration, investor services, wealth management, and property management. SS&C has a history of growth by acquisition, fending off potential competitors by buying them out. In 2018, the company made its largest ever move of this type, spending $5.4 billion to buy DST Systems, and earlier this fall SS&C announced that it will be purchasing Algorithmics Assets from IBM.In Q3 2019, SS&C reported solid results in terms of both EPS and gross revenues. The bottom-line earnings came in at 93 cents per share, 4 cents over the estimate and 14 cents over the year-ago figure. Revenues, at $1.15 billion, were 15% higher year-over-year. It was the third time in three quarters that the company had beaten the quarterly forecast.Turning to the Smart Score for SSNC, we find that the analysts, the bloggers, and the news are all bullish on the stock. News sentiment is 100% positive, meaning that there have been no negative articles on SSNC in the last week. This compares to a sector average of 63% bullish. The financial bloggers have also been 100% positive, against a sector average or 67%.Writing for Deutsche Bank, analyst Ashish Sabadra says, “Despite the recent run-up, SSNC stock is trading at a significant discount to peers and historical multiples due to concerns about organic revenue growth in 2020. We believe the pricing increase should help improve organic growth…” In line with that expectation, Sabadra has set a Buy rating and raised his price target from $64 to $75, implying a 25% upside potential for the stock. (To watch Sabadra’s track record, click here)SS&C’s Strong Buy consensus rating is based on 8 reviews, including 6 Buys and 2 Holds. Some analysts are still cautious due to the stock’s late-summer doldrums, but the majority agree with Sabadra’s estimate that this company will take off in the coming year. The average price target, $65, implies an upside of 9% from the trading price of $60.10. (See the SS&C Technologies stock analysis at TipRanks) Lattice Semiconductor Corporation (LSCC)This mid-cap chip company focuses on programmable logic devices and design-oriented intellectual property software. This niche, aimed at the market for customizable processor chips, has been highly successful, and Lattice has posted an astounding 192% gain in 2019. In ordinary numbers, the stock has risen from $7 in January to over $20 today. It’s a truly impressive performance.The Smart Score on LSCC reflects this. The analysts are bullish, and the bloggers have been giving positive reviews for the last 9 months. The year-to-date gain gives the stock high momentum, as nothing will attract investors faster than a visible winner. A survey of the hedge fund market shows that purchase activity in LSCC increased since the last quarter.Lattice’s Q3 results, like those for SS&C above, beat the forecasts in both earnings and revenues. EPS came in at 17 cents, against a 15-cent estimate and an 11-cent year-ago number. Gross revenues were reported at $103.5 million, a 1.9% gain from the previous year. LSCC is a stock that is clearly heating up, and shows no sign of slowing.Matt Ramsay, 5-star analyst with Cowen, attended Lattice’s most recent product launch last week and gave the stock a Buy rating. He’d come away from the session with a favorable impression, and wrote after the event, “Management debuted NEXUS, its next-gen platform for low-power/small footprint FPGAs. We came away impressed and believe the platform represents a critical milestone in the company's acceleration…” Ramsay’s bumped his price target up from $23 to $25, showing confidence in a 24% upside. (To watch Ramsay’s track record, click here)Lattice gets a unanimous Strong Buy consensus rating from the analysts, as 5 of Wall Street’s experts have rated the stock a Buy in the last three months. The stock’s $23.25 average price target suggests a premium of 15% to the current share price of $20.20. (See the Lattice Semiconductor stock analysis at TipRanks) Rapid7, Inc. (RPD)In today’s digital world, cybersecurity is an ever-growing need, and a company which can provide it is likely to have a path forward to success. Rapid7 provides just that, through data and analytic software solutions. RPD’s products and services collect and analyze data, provide context to the results, and give customers the ability to reduce exposure to digital threats and detect system compromises is real time.At a $2.8 billion market cap, Rapid7 is a mid-sized company holding its own in a large field. The company’s Q3 earnings showed a net profit where the Street had expected a loss. While modest, that 1-cent per share gain was far better than the 2-cent loss which had been predicted. The earnings were supported by gross revenues of $83.2 million, 3.7% higher than the $80.2 million estimate, and 33% higher year-over-year. Customer growth was up 17% from the year-ago quarter, and most importantly, annualized recurring revenue (ARR) gained 43%, reaching $310.2 million. In response to the strong quarter, management raised the forward guidance for 2019 revenue growth to the 32% to 33% range.As expected for a stock showing strong earnings and revenues, RPD is up for the year. The 80% gain in 2019 is almost triple the 27% gain on the S&P – and the year is not quite over yet. A look at RPD’s Smart Score demonstrates what is going right for the stock in the larger picture. The analyst consensus, blogger opinions, and hedge activity are all positive, but the most interesting factor may be the individual investors. The individual investor metric shows modest gains at both the 7 and 30-day time horizons.Top analysts are attracted to RPD shares. Matthew Hedberg, rated 9 overall in TipRanks’ analyst database, met with company management recently and looked at the Q3 numbers and forward guidance. He writes, “After spending the day with management, we feel better about the company's ability to deliver sustainable, above-market and profitable growth supported by several waves of product innovation.”In his investment thesis, Hedberg lays out the case for buying into RPD: “Its value proposition is to utilize massive amounts of data collected from the network and endpoints to help customers proactively prevent security breaches. ARR growth is the key metric, as management expects it to remain at or above 30% through 2020.” As expected, Hedberg gives this stock a Buy rating, and his $81 price target suggests a 45% upside potential. (To watch Hedberg’s track record, click here)RPD’s analyst consensus rating of Strong Buy reflects the stock’s strong performance. 10 out of 11 Wall Street experts have set Buy ratings on this stock in the past three months, while only 1 has put a Hold. The shares trade for $56, so the average price target of $67.73 implies a potential for 21% upside growth. (See the Rapid7 stock analysis at TipRanks)
If you own shares in Rapid7, Inc. (NASDAQ:RPD) then it's worth thinking about how it contributes to the volatility of...
(Bloomberg) -- Security researchers discovered vulnerabilities in cheap smartwatches for children that make it possible for strangers to override parental controls and track kids.Rapid7 Inc., a cybersecurity firm based in Boston, purchased three smartwatches on Amazon.com, costing from $20 to $35, according to Deral Heiland, research lead for IoT technology. He said the models -- GreaSmart Children’s SmartWatch, Jsbaby Game Smart Watch and SmarTurtle Smart Watch for Kids -- were picked randomly from dozens for sale on Amazon and marketed as appropriate for grade school-aged kids.All three devices offer location tracking, messaging and chat features. They were manufactured in China and shared nearly identical hardware and software. They also had similar security issues, Rapid7 found.The watches let authorized users view and change configuration details by texting the watch directly with certain commands. In practice, this didn’t work and “unlisted numbers could also interact with the watch,” Rapid7 said in a report.This security issue could be fixed with a vendor-supplied firmware update, but “such an update is unlikely to materialize given that the providers of these devices are difficult to impossible to locate,” the cybersecurity firm added.The watches have a default password of “123456,” but one of the watch’s manuals doesn’t mention the password, according to the researchers. Another mentioned the password in a blog but not in its printed material. The third doesn’t characterize the numbers as a password nor does it provide instructions on how to change it, according to the researchers.“Given an unchanged default password and a lack of SMS filtering, it is possible for an attacker with knowledge of the smartwatch phone number to assume total control of the device, and therefore use the tracking and voice chat functionality with the same permissions as the legitimate user (typically, a parent),” Rapid7 said in its report.An unauthorized user could shut off all the safety protocols a parent had set up on the smartwatch, Heiland said.Rapid7 said its researchers weren’t able to contact the sellers nor what they believe is the manufacturer of the watches, a Chinese company called 3g Electronics Co. The company didn’t respond to a message from Bloomberg News seeking comment.The GreaSmart Children’s SmartWatch is no longer for sale on Amazon, according to Rapid7. GreaSmart, Jsbaby, SmarTurtle didn’t respond to a requests for comment. Oltec, a merchant that sells the SmarTurtle watch on Amazon, didn’t respond to a message sent via Amazon’s site.“Consumers that are concerned with the safety, privacy, and security of their IoT devices and the associated cloud services are advised to avoid using any technology that is not provided by a clearly identifiable vendor, for what we hope are obvious reasons,” Rapid7 warned in its report.To contact the reporter on this story: Andrew Martin in New York at firstname.lastname@example.orgTo contact the editors responsible for this story: Tom Giles at email@example.com, Alistair Barr, Andrew PollackFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Is Rapid7 Inc (NASDAQ:RPD) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, unconventional data sources, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their consensus […]
Global investment bank, RBC Capital, is one of the finance world’s heavy hitters. It is the 5th largest in North America, and with 70 offices in 15 countries around the world, it has a stellar reputation. This international reputation and the financial clout that comes with it, naturally attracts top talent, and top talent can bring home the bacon, so to speak. It is no wonder then that RBC leads TipRanks’ list of Top Performing Research Firms.With this in mind, we decided to take a look at some of the recent stock recommendations from RBC analysts, specifically ones with potential for 30%+ gains ahead.Agile Therapeutics (AGRX)Agile Therapeutics shares took a nosedive in late October after briefing documents released by the FDA expressed concern regarding the “effectiveness in proportion to its safety,” of Twirla, the company’s contraceptive patch, ahead of an AdCom review. As it happens, the review panel voted in favor of approval, which coincidentally, sent the stock skyrocketing.Following the AdCom’s positive outcome, RBC surveyed physicians to better understand the experts’ view on Twirla. The results echoed those of the AdCom, and with the PDUFA set for November 16, the impression is that Twirla will most likely be granted approval by the FDA.RBC analyst Randall Stanicky noted, “We could see approval this week or alternatively a potential ~3month delay as FDA works through labeling; either way we think shares at these levels show attractive near-term upside… Our survey of 40 OB/GYNs was surprisingly bullish on desire for Twirla as a contraceptive option; this increases our conviction that there is a place for it in the market.”As a result, Stanicky reiterates a Buy rating on AGRX along with a $5.00 price target, which implies a whopping upside of 130% from current levels. (To watch Stanicky’s track record, click here)How does Stanicky's bullish bet weigh in against the Street? It appears the analyst is not the only one enthusiastic on this healthcare stock, with TipRanks analytics demonstrating AGRX as a Strong Buy. This breaks down into 5 "buy" ratings in the last three months. With a return potential of over 100%, the stock’s consensus target price stands at $4.50. (See Agile stock analysis on TipRanks)Rapid7 (RPD)Cyber-security firm, Rapid7, provides data and analytics software to help organizations keep their networks safe from malicious cyber threats. Basically, it does what it says on the tin and reduces risk across a connected environment.Last week, Rapid7 delivered stronger quarterly results than expected, with annualized recurring revenue (ARR) growing by 43% on top of 17% customer growth. Overall, the company posted earnings of one cent per share on revenue of $83.16 million, beating the loss of 3 cents and revenue of $80.12 million analysts expected. Therefore, the company has now raised 2019 revenue guidance from $319 million to $323.5 million.Citing Rapid7 as a favorite SMID-cap, RBC’s 5-star analyst Matthew Hedberg believes that although estimates have gone higher, they still look beatable. Hedberg noted, “ARR growth is the key metric, as management expects it to remain at or above 30% through 2020. While the stock has performed well, we continue to believe it represents an attractive investment… In addition to new customer additions, we believe 2020 should see the cross-sale of additional products like InsightIDR and InsightAppSec and longer-term InsightConnect. This value generation was shown in ARR per customer, which grew 22% y/y… Our estimates move higher, but we still believe upside remains through 2020…”This has led Hedberg to keep his Buy rating along with a price target of $81.00. With RPD currently trading at $51.08, this provides upside of about 60%. (To watch Hedberg’s track record, click here).Looking at the consensus breakdown, the cyber-security firm has amassed 8 Buys and 1 Hold in the last three months, making Rapid7 a Strong Buy. The average stock-price forecast is $65.50. Not quite as bullish as Hedberg, this target still provides upside of 28% from its current price. (See Rapid7 price targets and analyst ratings on TipRanks)Aprea Therapeutics (APRE)Aprea Therapeutics is a Boston, Massachusetts-based biopharma focused on developing and bringing to market novel cancer therapeutics that reactivate mutant tumor suppressor protein p53. Aprea’s main drug candidate is APR-246, a small molecule in clinical development designed to treat various forms of cancer with TP53 mutations. These are found in half of all cancers. Through its unique design, APR-246 is able to restore immune defenses and promote apoptosis of cancer cells.The company will present updated data from its phase II trial in December, and it believes APR-246 will be a first-in-class therapy if approved by regulators.RBC’s Gregory Renza agrees, saying, “We believe APRE’s small molecule p53 reactivator pipeline in oncology, led by APR-246, has ample potential given the data to date and catalyst setup expected over the year. We see APRE emerging as a competitive player in the oncology space, especially in severe TP53 populations where unmet need is high, and believe in its potential for long-term share appreciation as the programs continue to de-risk… If approved, we see prospects of $800M WW peak sales in MDS at a ~35% POS, driving 2/3 of our valuation.”Renza initiated coverage with a bullish call and set a price target of $33.00, indicating upside of over 32%. (To watch Renza’s track record, click here)It’s a tad quiet when it comes to analyst coverage, with only two other analysts currently providing ratings for APRE, both recommending a Hold. With an average price target of $26.33 providing a modest 5% upside from its current price, the biopharma newbie ranks as a Moderate Buy. (See Aprea price targets and analyst ratings on TipRanks)
Corey Thomas became the CEO of Rapid7, Inc. (NASDAQ:RPD) in 2012. First, this article will compare CEO compensation...
Rapid7 (RPD) delivered earnings and revenue surprises of 133.33% and 3.79%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Stock futures signal further gains for the market rally. RingCentral, Everbridge and Adobe earnings news offer hope for the software sector.
It was a rough fourth quarter for many hedge funds, which were naturally unable to overcome the big dip in the broad market, as the S&P 500 fell by about 4.8% during 2018 and average hedge fund losing about 1%. The Russell 2000, composed of smaller companies, performed even worse, trailing the S&P by more […]
Rapid7 (RPD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
It hasn't been the best quarter for Rapid7, Inc. (NASDAQ:RPD) shareholders, since the share price has fallen 23% in...
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
CFO of Rapid7 Inc (30-Year Financial, Insider Trades) Jeffrey Kalowski (insider trades) sold 37,500 shares of RPD on 08/15/2019 at an average price of $53.73 a share. Continue reading...
CEO of Rapid7 Inc (30-Year Financial, Insider Trades) Corey E. Thomas (insider trades) sold 20,000 shares of RPD on 08/07/2019 at an average price of $55.24 a share. Continue reading...